Investors in penny stocks know that they are an inherently risky proposition. That goes double for any investor just getting into this market. But with… Read More »6 Penny Stocks With 1,000% Upside Potential
Shares of the relatively unknown biopharmaceutical company discussed in today’s article have experienced extreme volatility this month, hitting their all-time low on June 2nd before proceeding to soar to their all-time high on June 10th.
“These are five stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential,” says the author of today’s… Read More »5 Stocks Under $10 With Big Upside Potential – Including 2 Microcap Biotech Stocks
The small-cap biopharmaceutical stock featured in today’s article is a Buy according to the consensus among analysts, who see upside potential of nearly 200% from current levels.
“Investors in biotech stocks need to find targets with positive catalysts on the near- to mid-term horizon, including promising drug candidates and/or novel approaches to unmet medical needs.”
Is the current downturn a good buying opportunity for biotech stocks? And, if so, which biotech stocks are the most promising picks for aggressive investors?
Two penny stocks that boast “Strong Buy” consensus ratings from the analyst community and massive upside potential.
Two clinical-stage biotech stocks with the potential to deliver gains of 100% or more.
“These are five stocks for very aggressive investors looking to get share-count leverage with stocks that have sizable upside potential,” declares the author of today’s… Read More »5 Aggressive Tech Plays Under $10
Among the three stocks highlighted in today’s article where analysts at RBC see upside potential over 100% – and which have all earned “Strong Buy” consensus analyst ratings – is “a pharmaceutical company with a unique niche.